NUVL
NASDAQNuvalent Inc. · Biotechnology
What if I bought 100 shares?
demo simulatorTrade Setup Generator
Confidence 79NUVL ranks in the top tier of AlphaRadar's Dollar Move scanner (96/100) thanks to a bullish MACD, 6.4× relative volume, and a near-term catalyst: phase 2 readout. Cup-and-handle forming on the daily; price is coiling beneath $5.00 horizontal resistance with rising RVOL and a fresh golden cross.
- Bullish: Phase 2 interim data due within the week, with management hinting at positive enrollment trends. Cash runway extends past the next two catalysts.
- Risks: Single-asset concentration, clinical risk, potential dilution if the print is soft.
- Setup: Cup-and-handle forming on the daily; price is coiling beneath $5.00 horizontal resistance with rising RVOL and a fresh golden cross.
- Catalyst: Phase 2 ALK+ NSCLC readout expected within 7 trading days. Avg historical move on similar prints: $2.10.
Position Size Calculator
Company Overview
Clinical-stage biopharmaceutical company developing precisely targeted therapies for clinically proven kinase targets in cancer.
Why This Stock Could Move
Phase 2 interim data due within the week, with management hinting at positive enrollment trends. Cash runway extends past the next two catalysts.
Binary trial outcome. A miss could halve the share price on the open.
Cup-and-handle forming on the daily; price is coiling beneath $5.00 horizontal resistance with rising RVOL and a fresh golden cross.
Single-asset concentration, clinical risk, potential dilution if the print is soft.
Phase 2 ALK+ NSCLC readout expected within 7 trading days. Avg historical move on similar prints: $2.10.
Movement Projection
News
- Nuvalent reaches enrollment milestone in Phase 2 trialBusiness Wire · 2h ago
- Buy-side coverage initiated at $7 targetBenzinga · 1d ago